Clinical Trial Update: Selumetinib for the Prevention of Plexiform Neurofibroma Growth in NF Type 1 [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial is evaluating selumetinib (Koselugo) to prevent plexiform neurofibroma growth in Neurofibromatosis type 1; the study is currently recru…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neurofibromatosis Type
• Plexiform Neurofibroma

Drugs mentioned

• Koselugo (selumetinib)

Snippet

Sponsor: University of Alabama at Birmingham | Conditions: Neurofibromatosis 1, Plexiform Neurofibroma | Phase 2 | Status: RECRUITING